Please visit our MS learning channel on YouTube, which provides hundreds of MS related topics from many of our video recorded education programs and archived here: -- Be empowered with MS views and news. Opt-in with us:

~~ Scroll left side of this blog for needed resources. Also, use our 'search by topic' tool, to find specific information.

Disclaimer: 'MS Views and News' DOES NOT endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, and procedures for your personal knowledge and to keep you informed of current health-related issues. It is not intended to be complete or exhaustive, nor is it a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.


Monday, September 19, 2016

European MS Guidance Taking Shape - ECTRIMS teases the first-ever MS drug guideline


Click here to receive MS news via e-mail

LONDON -- European researchers are putting finishing touches on the first-ever clinical guideline for drug treatment of multiple sclerosis, with a preview presented here in advance of its final release.
The guideline will discuss the considerations involved with each of the dozen available drugs but with little specific advice on how to choose among them, said Susana Otero-Romero, MD, of the Multiple Sclerosis Center of Catalonia in Barcelona, speaking at the European Committee for Treatment and Research in Multiple Sclerosis meeting here.
Selecting a drug will depend on patient characteristics, disease severity, drug safety profile, and accessibility – in combination with a conversation with the patient about their preferences, she said.
"The evidence thus far does not allow us to prioritize drugs," Otero-Romero told MedPage Today. "We're lacking head-to-head comparisons."
The guideline will also endorse ocrelizumab (tentative brand name Ocrevus) for primary progressive MS if the drug is approved before publication, Otero-Romero said.

MS Views and News
Providing educational information, resources and services for those affected by MS

No comments: